You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業-B(02616.HK)擬折價約14.99%配售最多8000萬股 總籌約2.35億港元
格隆匯 04-02 08:08

格隆匯4月2日丨基石藥業-B(02616.HK)發佈公吿,2025年4月2日(交易時段前),公司與配售代理(即摩根士丹利)訂立配售協議,據此,公司已有條件同意透過配售代理,以每股配售股份2.933港元的價格,向不少於六名承配人配售合共8000萬股配售股份。

配售價每股配售股份2.933港元,較2025年4月1日(即緊接配售協議日期前最後一個完整交易日)聯交所呈報的收市價每股股份3.45港元折讓約14.99%。最多8000萬股配售股份將佔本公吿日期公司現有已發行股本約6.23%及緊隨配售後經擴大已發行股本約5.86%(假設自本公吿日期起直至配售完成日期止公司的已發行股本並無變動)。配售股份將根據一般授權配發及發行,且無需取得任何股東批准。

假設所有8000萬股配售股份獲悉數認購,配售完成後,配售所得款項總額將為2.3464億港元,配售所得款項淨額估計為2.3229億港元。配售所得款項淨額預期將用於以下用途:(i)90%用於與集團“管線2.0”中的資產,尤其是CS5001(一款處於臨牀階段的ROR1 ADC(潛在同類最佳ROR1 ADC)),以及CS2009(一款靶向PD-1、VEGFA及CTLA-4的三特異性分子,潛在同類首創╱同類最優的下一代腫瘤免疫骨架)有關的進一步研發;及(ii)餘下所得款項淨額於適當時用於其他一般公司用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account